rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    TNDM
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Tandem upgraded, Insulet downgraded at Stifel on market for tubeless insulin pumps
      8h agoSeeking AlphaPODDTNDMSF
      This Elevance Health Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
      10h agoBenzingaTNDMELV
      Insulet downgraded, Tandem Diabetes upgraded: Wall Street's top analyst calls
      12h agoYahoo FinancePODDTNDM
      Tandem Diabetes shares climb 5% after Stifel upgrades stock to Buy
      13h agoInvesting.comTNDMSF
      Why is Tandem Diabetes Care stock rallying today?
      15h agoInvesting.comTNDM
      Stifel upgrades Tandem Diabetes stock rating on product pipeline
      17h agoInvesting.comTNDM
      Tandem: Wait Out The 2027 Transition Before Chasing The Turnaround

      Analyst rates Tandem Diabetes Care a Hold: Q3 revenue rose 13.8%, but U.S.

      Nov 16Seeking AlphaTNDM
      Tandem: Wait Out The 2027 Transition Before Chasing The Turnaround (NASDAQ:TNDM)
      Nov 16Seeking AlphaTNDM
      Tandem Mobi Becomes Only Insulin Pump Offering Both Tubed and Tubeless Wear Options
      Nov 13BenzingaTNDM
      Tandem Diabetes stock jumps 8% on FDA clearance for tubeless pump

      Investing.com -- Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) rose 8% after the company announced U.S. Food and Drug Administration clearance for its Tandem Mobi insulin pump to operate as a tubeless automated insulin delivery system with up to seven days of wear.

      Nov 13Yahoo FinanceTNDM
      Tandem Diabetes Care jumps 12% on FDA clearance for tubeless Mobi

      Tandem Diabetes Care shares rise 12% after FDA clears its tubeless Mobi system for up to seven days of wear; U.S.

      Nov 13Seeking AlphaTNDM
      Why is Tandem Diabetes Care stock surging today?
      Nov 13Investing.comTNDM
      Tandem Diabetes Care receives FDA clearance for tubeless insulin delivery system
      Nov 13Investing.comTNDM
      Can Tandem Diabetes Care (TNDM) Stay Cheap After Its Recall?

      Tandem Diabetes Care has been through a bruising stretch, with the share price down about 87.2% over the past five years, and yet the business still commands meaningful attention in insulin pump therapy. With that kind of long term decline and fresh headlines around its devices, the question now is whether the current valuation is properly supported by the cash flows the company is expected to generate. The roughly 87.2% share price decline over five years puts past investors under pressure...

      Nov 13Yahoo FinanceTNDM
      Tandem Diabetes Care Receives Multiple Health Canada Approvals for t:slim X2 Insulin Pump
      Nov 12Yahoo FinanceTNDM
      What Tandem Diabetes Care (TNDM) Said on Its Q3 Earnings Call
      Nov 6Yahoo FinanceTNDM
      Tandem Diabetes Care names next CEO
      Nov 6Yahoo FinanceTNDM
      Mizuho raises Tandem Diabetes Care stock price target on Q3 beat
      Nov 6Investing.comTNDM
      Tandem Diabetes Care Inc (TNDM) Q3 2026 Earnings Call Highlights: Record Revenue and Pipeline ...

      Tandem Diabetes Care Inc (TNDM) posts 14% revenue growth and record pump shipments while recalibrating 2027 outlook on slower pharmacy adoption and CEO transition.

      Nov 6Yahoo FinanceTNDM
      Earnings Beat Raises Fresh Questions For Tandem Diabetes Care Stock
      Nov 6Yahoo FinanceTNDM
      Tandem Diabetes Care (TNDM) Reports Q3 Earnings: What Key Metrics Have to Say
      Nov 5Yahoo FinanceTNDM
      Tandem Diabetes Care Q3 2026 Earnings Call Transcript
      Nov 5BenzingaTNDM
      Tandem Diabetes (NASDAQ:TNDM) reports upbeat Q3 2026, stock soars

      Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported Q3 2026 results topping the market’s revenue expectations, with revenue up 13.8% year on year to $283.7 million. The company expects the full year’s revenue to be around $1.08 billion, close to analysts’ consensus estimates. Its GAAP loss of $0.10 per share was 60.2% above analysts’ consensus estimates.

      Nov 5Yahoo FinanceTNDM
      Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Beats Revenue Estimates
      Nov 5Yahoo FinanceTNDM
      Tandem Diabetes names Jeannette Bankes as new CEO
      Nov 5Investing.comTNDM
      Tandem Diabetes Care Announces Third Quarter 2026 Financial Results
      Nov 5Yahoo FinanceTNDM
      Tandem Diabetes Care Announces Upcoming Conference Presentations
      Oct 30Yahoo FinanceTNDM
      Tandem Diabetes Care, Inc. (TNDM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
      Oct 29Yahoo FinanceTNDM
      Tandem Diabetes Care (TNDM) Stock May Be Underpriced Given Its Sales Base

      Tandem Diabetes Care shares have climbed back from a deep multi year slump, which puts a fresh spotlight on what investors are paying for each dollar of the company’s sales today. With the stock changing hands at about US$18.90, the key issue is how that price lines up with the underlying revenue base. The share price is still down about 86.2% over 5 years, which makes the current valuation conversation heavily anchored on whether the business now generates enough sales to support a...

      Oct 27Yahoo FinanceTNDM
      Tandem Diabetes Care Q2 2026 Earnings Call Transcript - Tandem Diabetes Care (NASDAQ:TNDM)

      Tandem Diabetes Care (NASDAQ:TNDM) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time

      Oct 12BenzingaTNDM
      Barclays Keeps Their Hold Rating on Tandem Diabetes Care (TNDM)

      Detailed price information for Tandem Diabetes Care (TNDM-Q) from The Globe and Mail including charting and trades.

      Oct 8The Globe and MailTNDM
      Tandem Diabetes Care (TNDM) Is Up 7.2% After International Launch Of Mobi Insulin Pump System

      Tandem Diabetes Care has recently launched its Tandem Mobi automated insulin delivery system in 12 countries across Europe and Israel, using Dexcom G7 continuous glucose monitoring and Control-IQ+ technology to automatically adjust insulin every 5 minutes. The international rollout of this small, iPhone-controlled pump with flexible wear options and a 200-unit cartridge broadens Tandem’s technology ecosystem for people living with diabetes outside the United States. We’ll now explore how...

      Oct 1Yahoo FinanceTNDM
      Q2 Earnings Highlights: Tandem Diabetes (NASDAQ:TNDM) Vs The Rest Of The Healthcare Technology Stocks
      Sep 30Yahoo FinanceTNDM
      Analysts’ Top Healthcare Picks: Tandem Diabetes Care (TNDM), Alterity Therapeutics (ATHE)

      Detailed price information for Alterity Therapeutics Ltd ADR (ATHE-Q) from The Globe and Mail including charting and trades.

      Sep 29The Globe and MailATHETNDM
      Tandem Diabetes Expands Insulin Delivery System to 12 New Countries

      Tandem Diabetes Care's (TNDM) Mobi automated insulin delivery system is now available in 12 countrie

      Sep 28Yahoo FinanceTNDM
      Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets

      MILAN, September 28, 2026--The Tandem Mobi automated insulin delivery system with Control-IQ+ automated insulin delivery technology is now available in 12 international markets.

      Sep 28Yahoo FinanceTNDM
      Truist Lowers Price Target on Tandem Diabetes Care to $28 From $31, Keeps Buy Rating

      Tandem Diabetes Care (TNDM) has an average rating of overweight and mean price target of $29, accord

      Sep 24Yahoo FinanceTNDM
      Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know

      Detailed price information for Zimmer Biomet Holdings (ZBH-N) from The Globe and Mail including charting and trades.

      Sep 23The Globe and MailQDELSGRYTNDMTXG
      Is Tandem Diabetes Care (TNDM) Undervalued As Investors Weigh Its 34% One Year Return?

      Tandem Diabetes Care (TNDM) is back in focus after recent share price swings, with the stock closing at US$16.87. Investors are weighing mixed return figures and fresh financial data on revenue and profit. The share price of US$16.87 comes after a sharp 24.42% decline in the 1 month share price return. However, the 3 month share price return is up 17.64%, and the 1 year total shareholder return of 34.21% indicates momentum that has been building over a longer period, despite weaker 3 and 5...

      Sep 20Yahoo FinanceTNDM
      Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?

      Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

      Sep 17Yahoo FinanceTNDM
      Tandem Diabetes Care: Stop Paying For Tomorrow's Profits - Strong Sell (NASDAQ:TNDM)
      Sep 11Seeking AlphaTNDM
      Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now

      TNDM's expanding pump lineup and pay-as-you-go model support growth prospects, though macro and competitive pressures remain.

      Sep 9Yahoo FinanceTNDM
      Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics
      Aug 21BenzingaBBNXTNDM
      William Blair initiates Tandem Diabetes stock with outperform rating
      Aug 21Investing.comTNDM

      This is the newest page. Registered accounts read further back.